YM BioSciences (YM.TO) Buy, Sell or Hold

YM BioSciences (YM.TO)

0.00

-0.00 (0.00%)

1 watching

TOP PICK

Recently suffered when phase 3 testing failed. Has cash in the bank, has a long runway (cash on a burn rate). Have 2 products in phase 3, one of which is approved in India and China. Great opportunities. Way undervalued.

BUY

In spite of its setback, he still likes. Risks/reward at this point is not bad. Speculative.

DON'T BUY

Was forced to cancel its cancer treatment trial. They do have some cash. Have another product in the pipeline, but it is in Cuba, which will keep US investors away.. It will take 6 months for the market to care again.

BUY

Tesmilifene is the 1st compound they’ll have pivotal phase 3 results on and the stock should move up strongly. Behind that, Nimotuzumab is a great compound that has some interesting phase 2 trials. Great risk/reward.

BUY

The only biotech stock that he owns. Accumulates on weakness. Had 2 trials on their cancer drug without getting approval, but this isn't a concern. Statistically difficult to get approval in 2 tries. Is expecting a successful end point. Have a fantastic pipeline of other drugs as well.

Showing 1 to 5 of 5 entries

YM BioSciences (YM.TO) Frequently Asked Questions

What is YM BioSciences stock symbol?

YM BioSciences is a OTC stock, trading under the symbol YM.TO (previously YM-T on Stockchase) on the (). It is usually referred to as or YM.TO

Is YM BioSciences a buy or a sell?

In the last year, there was no coverage of YM BioSciences published on Stockchase.

Is YM BioSciences a good investment or a top pick?

YM BioSciences was recommended as a Top Pick by Hugh Cleland, CFA on 2006-09-07. Read the latest stock experts ratings for YM BioSciences.

Why is YM BioSciences stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.

Is YM BioSciences worth watching?

In the last year, there was no coverage of YM BioSciences published on Stockchase.

Most Recent Experts

Kevin Simpson

Capital Wealth Planning

Karen Firestone, CEO, Aureus Asset Management

Aureus Asset Management

Bryn Talkington

Requisite Capital Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Brianne Gardner

Raymond James

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

YM BioSciences (YM.TO)